Novo Nordisk Signs Gene Editing Partnership With ElevateBio

Novo Nordisk A/S agreed to work together with ElevateBio LLC on gene editing therapies for rare diseases as well as disorders linked to obesity, a health condition that’s targeted by its blockbuster weight-loss shot Wegovy.

The Danish drugmaker is teaming up with ElevateBio’s Life Edit Therapeutics unit as it seeks to broaden its footprint in an area that may have wide potential, although they didn’t disclose specific targets.

Novo will pay an undisclosed initial amount in cash, plus as much as $335 million in development, regulatory and commercial milestones for each of the first two development programs and as much ...